Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Double-blind, Multicenter Parallel-group Clinical Study of Safety, Tolerability and Immunogenicity of the Betuvax-CoV-2 Recombinant COVID-19 Vaccine, Suspension for Intramuscular Administration in Healthy Adult Volunteers

NCT05270954 is registered in ClinicalTrials.gov with Artgen Biotech as lead sponsor.

NCT NCT05270954
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05270954 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Double-blind, Multicenter Parallel-group Clinical Study of Safety, Tolerability and Immunogenicity of the Betuvax-CoV-2 Recombinant COVID-19 Vaccine, Suspension for Intramuscular Administration in Healthy Adult Volunteers
Lead sponsor
Artgen Biotech
Phase
Phase 1/2
Overall status
Unknown status
Start date
October 14, 2021
Completion date
July 24, 2022
Enrollment
116 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19